Four affected cough syrups likely linked to the deaths of children in Gambia, manufactured by Maiden Pharmaceuticals, India has not been imported into the country and are not available for sale in the local market.
This was notified by the Ministry of Health (MoH) in a press release on Friday, with regards to the status of cough syrup for children in Brunei, following the global alert issued by the World Health Organisation (WHO) over four cough syrups believed to contain unacceptable amounts of toxic chemicals such as diethylene glycol and ethylene glycol, that could be linked to the deaths of 66 children in Gambia.
The MoH said it is aware of media reports of deaths in children in Gambia as well as Indonesia as a result of acute kidney injury.
To date, the ministry said no reports of adverse effects or deaths associated with cough syrup use among children in Brunei have been received by the health authorities. Based on available information, the MoH said it has concluded that there is no need to suspend the sale of all cough syrup in Brunei Darussalam.
More details on Borneo Bulletin Weekend
